Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

    NEXT STORY
    Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting
    PREV STORY
    Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer

    author_avatar
    NASDAQ Market News

    Cancer Genetics, Inc. Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions

    RUTHERFORD, N.J., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) an emerging ...

    author_avatar
    NASDAQ Market News

    Delcath Strengthens Executive Team with Appointment of Gerard Michel as Chief Executive Officer

    author_avatar
    NASDAQ Market News